Clinical trials: Erythropoietin, active
Left Ventricular Hypertrophy
Left Ventricular Hypertrophy in CKD Patients
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left…
- Trial name
- NCT07380893
- Testing
- transthoracic echocardiography
- Volunteers
- 100 people
- Sponsor
- Sohag University
MDS, Myelodysplastic Syndromes
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
- Trial name
- NCT05181735
- Testing
- Luspatercept Injection [Reblozyl], Eprex
- Where
- 41 sites in France, Italy
- Volunteers
- 150 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Anemia, Kidney Failure
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
Renal anemia is common in people receiving long-term hemodialysis and is usually treated with erythropoiesis-stimulating agents (ESAs).
- Conditions
- Anemia, Kidney Failure, End-Stage Renal Disease, Renal Dialysis
- Trial name
- L-CAR-ESA (NCT07160452)
- Testing
- Levocarnitine Injection, Usual ESA-Based Anemia Care
- Volunteers
- 94 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
The goal of this observational study is to characterize the diagnostic and therapeutic management of autoimmune cytopenias including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune…
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia
- Trial name
- AIHA ITP CIN (NCT05931718)
- Testing
- cytokine essays, NGS, Fecal microbiome
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Myelodysplastic Syndromes (MDS)
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
The primary objective of this study is to describe the response to treatment with biosimilar EPO alpha in MDS patients who had already been treated with "originator" EPO alpha and were responsive, and in patients who started…
- Trial name
- NCT06764511
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Chronic Kidney Disease (CKD), Hemodialysis Complication
ESA Hyporesponsiveness in Hemodialysis Patients
This prospective cohort study aims to evaluate the development, persistence, and recovery of erythropoiesis-stimulating agent (ESA) hyporesponsiveness among patients receiving maintenance hemodialysis.
- Conditions
- Chronic Kidney Disease (CKD), Hemodialysis Complication, Anemia
- Trial name
- NCT07855458
- Volunteers
- 200 people
- Sponsor
- Assiut University
Dialysis; Complications, Chronic Kidney Disease 5D
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
This study is a prospective, multicenter, parallel-controlled, open-label clinical trial, planned to be conducted across multiple research centers in various provinces and cities in China.
- Conditions
- Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia
- Trial name
- PANGU-stepup (NCT07045155)
- Testing
- The rHuEPO Monotherapy Group (Control Group), The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group), The Pegmolesatide Monotherapy Group (Experimental group)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Acute Respiratory Distress Syndrome
The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment.
- Trial name
- NCT05857891
- Testing
- Human erythropoietin injection, 0.9%NaCl
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Luspatercept, Epoetin
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT.
- Conditions
- Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
- Trial name
- NCT07636486
- Testing
- Luspatercept, Epoetin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Anemia, Iron Deficiency Anemia
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery.
- Conditions
- Anemia, Iron Deficiency Anemia, Perioperative, Transfusion
- Trial name
- CIPAT (NCT06012760)
- Testing
- Iron sucrose, Human Erythropoietin Injection, Vitamin C, Standard Medical Care
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anemia
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India
- Trial name
- NCT05891249
- Testing
- Luspatercept
- Where
- 9 sites in India
- Volunteers
- 85 people
- Sponsor
- Bristol-Myers Squibb
Neonatal Hypoxic Ischemic Encephalopathy
Erythropoietin in HIE Neonate
this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic…
- Trial name
- NCT06590155
- Testing
- Erythropoietin
- Where
- Egypt
- Volunteers
- 3 people
- Sponsor
- Assiut University
Healthy
Identifying Biological Markers for Altitude Exposure and Use of Recombinant Human Erythropoietin (rHuEPO)
The project represents a well powered study of the human response to altitude exposure combined with rHuEPO treatment. A total of 20 male and 20 female non-competing athletes will participate.
- Trial name
- NCT04227665
- Testing
- Sea level, Altitude
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Anemia
Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia.
The goal of this clinical trial is to learn if Spironolactone drug works to treat anemia in hemodialysis pediatric patients. It will also learn about the safety of Spironolactone drug.
- Trial name
- NCT07715318
- Testing
- Spironolactone (drug), Iron Supplement, Erythropoietin stimulating agent
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Erythropoietin Adverse Reaction
The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2.
- Trial name
- EPOASA (NCT04330729)
- Testing
- Acetylsalicylic acid
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Zealand University Hospital
Myelodysplastic Syndromes
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: Either at diagnosis Or at the…
- Trial name
- EPO-PRETAR (NCT03223961)
- Testing
- EPREX
- Where
- 39 sites in France
- Volunteers
- 124 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
- Trial name
- NCT06983756
- Testing
- Erythropoietin
- Volunteers
- 66 people
- Sponsor
- Fayoum University
Intraventricular Hemorrhage of Prematurity
Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
Very preterm infants are prone to numerous medical complications with lifelong impact. Amongst the most serious neurologically are white matter injury (WMI), intraventricular hemorrhage (IVH) and the subsequent progression to…
- Trial name
- SCEMPI (NCT05617833)
- Testing
- MLT+EPO
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Myelodysplastic Syndromes
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at…
- Trial name
- COMMANDS (NCT03682536)
- Testing
- Luspatercept, Epoetin alfa
- Where
- 226 sites in United States, Australia and 24 more
- Volunteers
- 363 people
- Sponsor
- Celgene
Anemia, Chronic Kidney Disease
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D
- Trial name
- NCT07119372
- Testing
- BCD-131 (pegdarbepoetin beta), Mircera (methoxypolyethylene glycol-epoetin beta)
- Where
- 14 sites in Russia
- Volunteers
- 228 people
- Sponsor
- Biocad